{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:38:27Z","timestamp":1789540707330,"version":"build-2803163510"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153429"],"award-info":[{"award-number":["PJT-153429"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hamilton Academic Health Sciences Organization","award":["HAH-16-04"],"award-info":[{"award-number":["HAH-16-04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Substance use disorders are highly prevalent among individuals with psychotic disorders and are associated with negative outcomes. This study aims to explore differences in characteristics and treatment outcomes for individuals with psychotic disorders when compared with individuals with other nonpsychotic psychiatric disorders enrolled in treatment for opioid use disorder (OUD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected from a prospective cohort study of 415 individuals enrolled in outpatient methadone maintenance treatment (MMT). Psychiatric comorbidity was assessed using the Mini-International Neuropsychiatric Interview. Participants were followed for 12 months. Participant characteristics associated with having a psychotic disorder versus another nonpsychotic psychiatric disorder were explored by logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Altogether, 37 individuals (9%) with a psychotic disorder were identified. Having a psychotic disorder was associated with less opioid-positive urine drug screens (odds ratio [OR] = 0.97, 95% confidence interval [CI] = 0.95, 0.99, P = .046). Twelve-month retention in treatment was not associated with psychotic disorder group status (OR = 0.73, 95% CI = 0.3, 1.77, P = .485). Participants with psychotic disorders were more likely to be prescribed antidepressants (OR = 2.12, 95% CI = 1.06, 4.22, P = .033), antipsychotics (OR = 3.57, 95% CI = 1.74, 7.32, P = .001), mood stabilizers (OR = 6.61, 95% CI = 1.51, 28.97, P = .012), and benzodiazepines (OR = 2.22, 95% CI = 1.11, 4.43, P = .024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and Conclusions<\/jats:title>\n                    <jats:p>This study contributes to the sparse literature on outcomes of individuals with psychotic disorders and OUD-receiving MMT. Rates of retention in treatment and opioid use are encouraging and contrast to the widely held belief that these individuals do more poorly in treatment. Higher rates of coprescription of sedating and QTc-prolonging medications in this group may pose unique safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schizbullopen\/sgaa007","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T11:19:54Z","timestamp":1583147994000},"source":"Crossref","is-referenced-by-count":16,"title":["Psychosis and Comorbid Opioid Use Disorder: Characteristics and Outcomes in Opioid Substitution Therapy"],"prefix":"10.1093","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8183-774X","authenticated-orcid":false,"given":"Rachel","family":"Lamont","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Rosic","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika","family":"Sanger","sequence":"additional","affiliation":[{"name":"Medical Sciences Graduate Program, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Samaan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"2020072705065264700_CIT0001","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annu Rev Public Health."},{"issue":"21","key":"2020072705065264700_CIT0002","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMp1011512","article-title":"A flood of opioids, a rising tide of deaths","volume":"363","author":"Okie","year":"2010","journal-title":"N Engl J Med."},{"issue":"9904","key":"2020072705065264700_CIT0003","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(13)61530-5","article-title":"Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Degenhardt","year":"2013","journal-title":"Lancet."},{"key":"2020072705065264700_CIT0004","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2147\/NDT.S129480","article-title":"The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study","volume":"13","author":"Rosic","year":"2017","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"6","key":"2020072705065264700_CIT0005","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull."},{"issue":"10100","key":"2020072705065264700_CIT0006","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(17)32130-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Abajobir","year":"2017","journal-title":"Lancet."},{"issue":"11","key":"2020072705065264700_CIT0007","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00005053-198711000-00001","article-title":"A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice","volume":"175","author":"Schneier","year":"1987","journal-title":"J Nerv Ment Dis."},{"issue":"19","key":"2020072705065264700_CIT0008","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA."},{"issue":"2\u20133","key":"2020072705065264700_CIT0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.psychres.2012.05.028","article-title":"Assessing illicit drug use among adults with schizophrenia","volume":"200","author":"Van Dorn","year":"2012","journal-title":"Psychiatry Res."},{"key":"2020072705065264700_CIT0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1192\/bjp.181.5.393","article-title":"Psychosis and drug dependence: results from a national survey of prisoners","volume":"181","author":"Farrell","year":"2002","journal-title":"Br J Psychiatry."},{"key":"2020072705065264700_CIT0011","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.schres.2017.05.004","article-title":"Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population","volume":"194","author":"Chiappelli","year":"2018","journal-title":"Schizophr Res."},{"key":"2020072705065264700_CIT0012","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0920-9964(98)00161-3","article-title":"Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes","volume":"35","author":"Dixon","year":"1999","journal-title":"Schizophr Res."},{"issue":"2\u20133","key":"2020072705065264700_CIT0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.schres.2011.07.032","article-title":"Substance use and schizophrenia: adverse correlates in the CATIE study sample","volume":"132","author":"Kerfoot","year":"2011","journal-title":"Schizophr Res."},{"issue":"4","key":"2020072705065264700_CIT0014","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40429-014-0034-7","article-title":"Pharmacotherapy of co-occurring schizophrenia and substance use disorders","volume":"1","author":"Akerman","year":"2014","journal-title":"Curr Addict Rep."},{"issue":"18","key":"2020072705065264700_CIT0015","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N Engl J Med."},{"issue":"2","key":"2020072705065264700_CIT0016","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pnpbp.2005.10.007","article-title":"Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study","volume":"30","author":"Gerra","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"2020072705065264700_CIT0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12991-018-0185-3","article-title":"The long-term outcome of patients with heroin use disorder\/dual disorder (chronic psychosis) after admission to enhanced methadone maintenance","volume":"17","author":"Maremmani","year":"2018","journal-title":"Ann Gen Psychiatry."},{"issue":"5","key":"2020072705065264700_CIT0018","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00131746-200509000-00005","article-title":"Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations","volume":"11","author":"Ziedonis","year":"2005","journal-title":"J Psychiatr Pract."},{"key":"2020072705065264700_CIT0019","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/NDT.S66234","article-title":"Genetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: a pilot study","volume":"10","author":"Samaan","year":"2014","journal-title":"Neuropsychiatr Dis Treat."},{"key":"2020072705065264700_CIT0020","first-page":"2239","article-title":"Evaluation of clinical and inflammatory profile in opioid addiction patients with comorbid pain: results from a multicenter investigation","volume":"10","author":"Dennis","year":"2014","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"9596","key":"2020072705065264700_CIT0021","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet."},{"key":"2020072705065264700_CIT0022","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry."},{"key":"2020072705065264700_CIT0023","first-page":"1","author":"Apotex","year":"2017"},{"issue":"12","key":"2020072705065264700_CIT0024","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1046\/j.1360-0443.1998.9312185711.x","article-title":"The Maudsley addiction profile (MAP): a brief instrument for assessing treatment outcome","volume":"93","author":"Marsden","year":"1998","journal-title":"Addiction."},{"key":"2020072705065264700_CIT0025","author":"IMDx I."},{"issue":"2","key":"2020072705065264700_CIT0026","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1176\/appi.ps.201300235","article-title":"Medication-assisted treatment with methadone: assessing the evidence","volume":"65","author":"Fullerton","year":"2014","journal-title":"Psychiatr Serv."},{"issue":"12","key":"2020072705065264700_CIT0027","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol."},{"key":"2020072705065264700_CIT0028","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s13063-015-0942-4","article-title":"Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria","volume":"16","author":"Dennis","year":"2015","journal-title":"Trials."},{"issue":"11","key":"2020072705065264700_CIT0029","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.281.11.1000","article-title":"Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial","volume":"281","author":"Strain","year":"1999","journal-title":"JAMA."},{"issue":"1\u20133","key":"2020072705065264700_CIT0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.forsciint.2013.01.028","article-title":"A review of methadone deaths between 2001 and 2005 in Victoria, Australia","volume":"226","author":"Pilgrim","year":"2013","journal-title":"Forensic Sci Int."},{"issue":"1","key":"2020072705065264700_CIT0031","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict."},{"issue":"3","key":"2020072705065264700_CIT0032","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jsat.2011.05.001","article-title":"Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study","volume":"41","author":"Cousins","year":"2011","journal-title":"J Subst Abuse Treat."},{"issue":"3","key":"2020072705065264700_CIT0033","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/1755-5922.12120","article-title":"Methadone therapy in underserved urban community: QTc prolongation and life-threatening ventricular arrhythmias","volume":"33","author":"Chowdhury","year":"2015","journal-title":"Cardiovasc Ther."},{"key":"2020072705065264700_CIT0034","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","article-title":"Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment \u2013 a nation-wide register-based open cohort study","volume":"174","author":"Abrahamsson","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"1\u20132","key":"2020072705065264700_CIT0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","article-title":"A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders","volume":"225","author":"Sendt","year":"2015","journal-title":"Psychiatry Res."},{"issue":"5","key":"2020072705065264700_CIT0036","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/acps.12722","article-title":"Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study","volume":"135","author":"Verdoux","year":"2017","journal-title":"Acta Psychiatr Scand."},{"issue":"9","key":"2020072705065264700_CIT0037","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can J Psychiatry."},{"issue":"2","key":"2020072705065264700_CIT0038","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/archpsyc.1982.04290020021004","article-title":"Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome","volume":"39","author":"Rounsaville","year":"1982","journal-title":"Arch Gen Psychiatry."},{"issue":"3","key":"2020072705065264700_CIT0039","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0376-8716(00)00148-4","article-title":"The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients","volume":"61","author":"Cacciola","year":"2001","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"2020072705065264700_CIT0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jsat.2006.03.012","article-title":"Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS)","volume":"30","author":"Havard","year":"2006","journal-title":"J Subst Abuse Treat."},{"issue":"5","key":"2020072705065264700_CIT0041","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: a primer for physicians","volume":"26","author":"Shrank","year":"2011","journal-title":"J Gen Intern Med."},{"issue":"1","key":"2020072705065264700_CIT0042","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13011-018-0177-y","article-title":"Comorbid opioid use is undertreated among forensic patients with schizophrenia","volume":"13","author":"Kivimies","year":"2018","journal-title":"Subst Abuse Treat Prev Policy."},{"issue":"9","key":"2020072705065264700_CIT0043","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ."}],"container-title":["Schizophrenia Bulletin Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizbullopen\/advance-article-pdf\/doi\/10.1093\/schizbullopen\/sgaa007\/32882317\/sgaa007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/schizbullopen\/article-pdf\/1\/1\/sgaa007\/33534146\/sgaa007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/schizbullopen\/article-pdf\/1\/1\/sgaa007\/33534146\/sgaa007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T05:07:29Z","timestamp":1595826449000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article\/doi\/10.1093\/schizbullopen\/sgaa007\/5771442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/schizbullopen\/sgaa007","relation":{},"ISSN":["2632-7899"],"issn-type":[{"value":"2632-7899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2020,1,1]]},"article-number":"sgaa007"}}